Biotech stocks drop 5% within 30 days of Makary's departure

Investors may interpret Makary's exit as a negative signal for regulatory predictability, particularly for biotech firms reliant on FDA timelines. Past leadership changes at FDA have triggered short-term stock declines in the biotech sector.

Implied probability (Yes)

65%